Drug Information

Drug (ID: DG00908) and It's Reported Resistant Information

• Name: Vindesine
• Synonyms: Vindesine; 53643-48-4; vindesine sulfate; Desacetylvinblastine amide; Vincaleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)-; CHEBI:36373; Desacetylvinblastine amide sulfate; C43H55N5O7; Vindesine (USAN/INN); SCHEMBL4420; methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; CHEMBL219146; DTXSID6023739; HMS2090E15; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; EX-A3837; ZINC8214470; STL565153; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; AKOS037623357; MCULE-7368625095; methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; D06304; AB00698294-03; AB01275494-01; hanoazacycloundecino[5,4-b]indole-9-carboxylate; 643V484; Q416660; Q-100607; BRD-K59753975-065-01-3; methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2(7),3,5,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5,7,9-tetraene-13-carboxylate; methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate; methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-met
• Indication:
  In total 1 Indication(s)
  Acute lymphoblastic leukaemia [ICD-11: 2A70]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Esophageal cancer [ICD-11: 2B70]; [1]
• Target: Tubulin beta (TUBB); NOUNIPROTAC; [1]
• Formula: C43H55N5O7
• IsoSMILES: CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
• InChI: 1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1
• InChIKey: HHJUWIANJFBDHT-KOTLKJBCSA-N
• PubChem CID: 40839
• ChEBI ID: CHEBI:36373
• TTD Drug ID: D04RLY
• VARIDT ID: DR00397
• INTEDE ID: DR1693
• DrugBank ID: DB00309

Type(s) of Resistant Mechanism of This Drug

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Esophageal cancer [ICD-11: 2B70]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: Multidrug resistance protein 1 (ABCB1) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Esophageal squamous cell carcinoma [ICD-11: 2B70.3]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: B16-F10 cells; Skin; Mus musculus (Mouse); CVCL_0159
• In Vitro Model: BHT101 cells; Lymph node; Homo sapiens (Human); CVCL_1085
• In Vitro Model: BHT-101 cells; Thyroid gland; Homo sapiens (Human); CVCL_1085
• In Vitro Model: C2C12 mouse skeletal muscle cells; Skeletal muscle; Mus musculus (Mouse); CVCL_0188
• In Vitro Model: C6 cells; Brain; Rattus norvegicus (Rat); CVCL_0194
• In Vitro Model: C643 cells; Thyroid gland; Homo sapiens (Human); CVCL_5969
• In Vitro Model: Caco-2 cells; Colon; Homo sapiens (Human); CVCL_0025
• In Vitro Model: CAL-1 [Human plasmacytoid dendritic] cells; Pleural effusion; Homo sapiens (Human); CVCL_5G46
• Experiment for Molecule Alteration: DNA and RNA analysis
• Experiment for Drug Resistance: Colony Formation
• Mechanism Description: In SH-1-V8 cells, cellular accumulation of vincristine decreased and an MDR reversal agent, cepharanthine, potentiated the cytoci-dal action of vindesine. The expression of MDR 1 mRNA was enhanced and amplification of the MDR1 gene was observed in clones SH-1-V4, SH-1-V5, SH-1-V6, SH-1-V7 and SH-1-V8; expression of MDR1 mRNA was detectable without gene amplification in the remaining 3 clones. The enhanced expression of the MDR1 gene may be involved in the acquisition of vindesine resistance in human esophageal cancer cells.

References

• Ref 1: Enhanced expression of the multidrug resistance gene in vindesine-resistant human esophageal cancer cells .Oncology. 1994 Sep-Oct;51(5):440-5. doi: 10.1159/000227380. 10.1159/000227380